AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma

Figure 4 Subgroup analysis of survival outcomes stratified by clinical and pathological characteristics. A: Overall survival (OS) and progression-free survival (PFS) of patients without portal vein tumor thrombus in the training cohort based on the AADN score (log-rank, OS: P < 0.0001, PFS: P = 0.0004); B: OS and PFS of patients with portal vein tumor thrombus in the training cohort based on the AADN score (log-rank, OS: P = 0.0161, PFS: P = 0.0262); C: OS and PFS of patients with AFP < 100 ng/mL in the training cohort based on the AADN score (log-rank, OS: P = 0.0486, PFS: P = 0.2902); D: OS and PFS of patients with AFP ≥ 100 ng/mL in the training cohort based on the AADN score (log-rank, OS: P = 0.0022, PFS: P = 0.0051); E: OS and PFS of Barcelona Clinic Liver Cancer stage B patients in the training cohort based on the AADN score (log-rank, OS: P = 0.0007, PFS: P = 0.0379); F: OS and PFS of Barcelona Clinic Liver Cancer stage C patients in the training cohort based on the AADN score (log-rank, OS: P = 0.0002, PFS: P = 0.0003). PVTT: Portal vein tumor thrombus; OS: Overall survival; AFP: Alpha-fetoprotein; PFS: Progression-free survival; BCLC: Barcelona Clinic Liver Cancer.